Overview

Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

To assess safety, efficacy and impact of Lopinavir/ritonavir 400/100mg bid or Lopinavir/ritonavir 600/150mg bid in combination with rifampicin-containing anti-TB therapy.

Phase:

Phase 2

Details

Lead Sponsor:

The HIV Netherlands Australia Thailand Research Collaboration

Collaborator:

Department of Disease Control, Ministry of Public Health Thailand

Treatments:

Antitubercular Agents
Lopinavir
Reverse Transcriptase Inhibitors
Rifampin
Ritonavir